Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
JAZZ Stock Chart & Stats
$190.46
-$1.17(-0.95%)
At close: 4:00 PM EST
$190.46
-$1.17(-0.95%)
Day’s Range― - ―
52-Week Range$95.49 - $198.00
Previous CloseN/A
Volume75.28K
Average Volume (3M)952.68K
Market Cap
$11.72B
Enterprise Value$15.51B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$5.41B
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 06, 2026EPS Estimate
4.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.64
Shares Outstanding61,560,350
10 Day Avg. Volume1,393,818
30 Day Avg. Volume952,678
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio7.99
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit4.12
Enterprise Value/Ebitda111.49
Forecast
1Y Price Target
$232.18Price Target Upside21.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)23.76
Revenue Forecast (FY)$4.44B
Bulls Say, Bears Say
Bulls Say
Launch Execution And Revenue OutlookStrong Modeyso launch momentum, continued Epidiolex strength, and revenue guidance that eased investor concerns indicate launch execution could underpin sustained top-line growth and prompt re-rating of the stock.
Oncology Pivotal Trial And Market PotentialPositive Phase 3 findings and expert support position the HER2-targeted antibody zanidatamab to become a new first-line backbone in gastric cancer, creating a clear regulatory and commercial pathway that could drive substantial upside if approved.
Product Differentiation And Formulary PositioningLow-sodium oxybate's differentiated safety profile combined with maintained formulary placement and the idiopathic hypersomnia approval is expected to sustain patient starts and support branded oxybate revenue resilience.
Bears Say
Clinical Uncertainty And Safety SignalsInterim analyses that missed conventional significance coupled with higher diarrhea rates observed with zanidatamab create outcome and tolerability uncertainty that could complicate approval timing and market uptake pending full trial results.
Oxybate Competition And Legacy Product Phase-outGrowth in high-sodium generic oxybates and the planned phase-out of a legacy branded product are likely to pressure aggregate oxybate revenues and constrain overall sleep-category growth.
Pipeline SetbackDiscontinuation of the orexin 2 receptor agonist in favor of an early-stage backup increases pipeline execution risk and reduces near-term innovation prospects for the sleep franchise.
Jazz Pharmaceuticals News
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $95.49 and its highest was $198.00 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $11.72B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is May 06, 2026 which is in 63 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Feb 24, 2026. The company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $6.518 by $0.122.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 4.55.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 61,560,350 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.64 in its last earnings report, beating expectations of $6.518. Following the earnings report the stock price went up 13.231%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$232.18 (21.90% Upside)
$232.18 (21.90% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 318.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.69%
12-Months-Change
Fundamentals
Return on Equity
-8.47%
Trailing 12-Months
Asset Growth
-2.94%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ Company Deck
JAZZ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution and multiple material positives: record revenues, blockbuster Epidiolex, robust Xywav performance, the highly important practice-changing Phase III zanidatamab data with an expedited regulatory path, a promising Modeyso launch, substantial cash generation, and meaningful litigation and tax benefits. Offsetting items include evolving competitive pressure in the sleep (high-sodium oxybate) market leading to an expected modest decline in Rare Sleep revenue in 2026, increased R&D investment and modest margin pressure, the termination of one orexin program (JZP441), a conservative 2026 top-line growth guide (~2.5% at midpoint) and no EPS guidance, and potential share dilution from convertible note conversions. Overall, the positive commercial momentum, high-impact oncology data and strong financial position outweigh the challenges and near-term headwinds.View all JAZZ earnings summariesJAZZ Stock 12 Month Forecast
Average Price Target
$232.18
▲(21.90% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Bio-Techne
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
3.66% Insiders
30.44% Mutual Funds
19.75% Other Institutional Investors
21.34% Public Companies and
Individual Investors